TEK and glioblastoma: Now, Injune Kim at the Korea Advanced Institute of Science and Technology, Weon Sup Lee at PharmAbcine Inc., both in Daejeon, South Korea, and co-workers have developed a Tie2-activating antibody that effectively stops vascular abnormalization in and around glioblastoma in the spontaneous mouse tumor model.